VIGAFYDE
Growthvigabatrin
NDAORALSOLUTION
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
4
Mechanism of Action
Pharmacologic Class:
Anti-epileptic Agent
Clinical Trials (4)
Vigabatrin for the Treatment of Cocaine Dependency
Started Jan 2011
Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence
Started Jul 2008
Vigabatrin for Treatment of Cocaine Dependence
Started Jan 2008
Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence
Started Apr 2007
Loss of Exclusivity
LOE Date
Oct 17, 2042
202 months away
Patent Expiry
Oct 17, 2042